Tiotropium respimat® add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of TH2 inflammatory status

Allergy, Asthma and Clinical Immunology

Volumn 10, Issue 2, 2014, Pages

  Yang, W H ^a   Casale, T ^b   Bateman, E D ^c   Dahl, R ^d   Pizzichini, E ^e   Vandewalker, M ^f   Virchow, J C ^g   Engel, M ^h   Moroni Zentgraf, P M ^h   Schmidt, H ^h   Kerstjens, H A M ⁱ  

^a Allergy and Asthma Research Centre   (Canada)

^b CREIGHTON UNIVERSITY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^f Clinical Research of the Ozarks   (United States)

^g ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ADD ON THERAPY; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TH2 CELL; TREATMENT OUTCOME;

EID: 84961644544     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-10-S2-A52     Document Type: Article

References (0)